Skip to main content
Premium Trial:

Request an Annual Quote

Synthetic Genomics, IDT Partner on Small Synthetic Gene Products

NEW YORK (GenomeWeb News) – Synthetic Genomics and Integrated DNA Technologies today announced a deal to manufacture, market, and commercialize small synthetic gene products.

The deal, the terms of which were not disclosed, calls for the companies to construct custom, synthetic, double-stranded nucleic acids up to 5 kilobases. IDT will combine its expertise in custom oligonucleotide manufacturing with Synthetic Genomics' technology to assemble small gene constructs.

The collaboration is expected to result in "more affordable, efficient gene synthesis products that can be delivered more quickly to the synthetic biology community," Joe Walder, founder and CEO of IDT, said in a statement.

Craig Venter, founder and CEO of Synthetic Genomics, called the deal "a key component to advance our synthetic DNA business."

A few months ago Synthetic Genomics and Plenus announced the formation of a new company called Agradis to develop and commercialize products leveraging new genomics technologies.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.